Cargando…

ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs

Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasud...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagano, Luca, Lee, Jason William, Posarelli, Matteo, Giannaccare, Giuseppe, Kaye, Stephen, Borgia, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648286/
https://www.ncbi.nlm.nih.gov/pubmed/37959203
http://dx.doi.org/10.3390/jcm12216736
_version_ 1785135304414330880
author Pagano, Luca
Lee, Jason William
Posarelli, Matteo
Giannaccare, Giuseppe
Kaye, Stephen
Borgia, Alfredo
author_facet Pagano, Luca
Lee, Jason William
Posarelli, Matteo
Giannaccare, Giuseppe
Kaye, Stephen
Borgia, Alfredo
author_sort Pagano, Luca
collection PubMed
description Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects.
format Online
Article
Text
id pubmed-10648286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106482862023-10-25 ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs Pagano, Luca Lee, Jason William Posarelli, Matteo Giannaccare, Giuseppe Kaye, Stephen Borgia, Alfredo J Clin Med Review Rho kinase (ROCK) inhibitors have gained significant attention as emerging novel treatment options in the field of ophthalmology in recent years. The evidence supporting their efficacy in glaucoma and corneal pathology includes both in vitro and clinical studies. Among the available options, ripasudil and netarsudil have emerged as the leading ROCK inhibitors, and some countries have approved these therapeutic options as treatments for glaucoma. Various dosing regimens have been studied, including monotherapy and combination therapy, especially for patients with secondary glaucoma who are already on multiple medications. Another rising application of ROCK inhibitors includes their use as an adjunct in surgical procedures such as Descemetorhexis Without Endothelial Keratoplasty (DWEK), Descemet Stripping Only (DSO) to accelerate visual recovery, glaucoma surgeries to reduce scarring process and allow better intraocular pressure (IOP) control, or after complicated anterior segment surgery to treat corneal oedema. This article provides a comprehensive overview of the existing literature in the field, offering recommendations for prescribing ROCK inhibitors and also discussing patient selection, drug efficacy, and possible adverse effects. MDPI 2023-10-25 /pmc/articles/PMC10648286/ /pubmed/37959203 http://dx.doi.org/10.3390/jcm12216736 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pagano, Luca
Lee, Jason William
Posarelli, Matteo
Giannaccare, Giuseppe
Kaye, Stephen
Borgia, Alfredo
ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
title ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
title_full ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
title_fullStr ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
title_full_unstemmed ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
title_short ROCK Inhibitors in Corneal Diseases and Glaucoma—A Comprehensive Review of These Emerging Drugs
title_sort rock inhibitors in corneal diseases and glaucoma—a comprehensive review of these emerging drugs
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10648286/
https://www.ncbi.nlm.nih.gov/pubmed/37959203
http://dx.doi.org/10.3390/jcm12216736
work_keys_str_mv AT paganoluca rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs
AT leejasonwilliam rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs
AT posarellimatteo rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs
AT giannaccaregiuseppe rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs
AT kayestephen rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs
AT borgiaalfredo rockinhibitorsincornealdiseasesandglaucomaacomprehensivereviewoftheseemergingdrugs